UPDATE 1-Theratechnologies says FDA delays fat drug review meet

* Says FDA postpones tesamorelin review date to July 27

Feb 25 (Reuters) - Canada's Theratechnologies Inc (TH.TO) said U.S. health regulators would extend till July the review date of its experimental drug to treat HIV-associated excess abdominal fat, due to a delay in the meeting of an advisory committee.

The review for the drug tesamorelin, earlier scheduled for March 29, can only be held following the meeting of the U.S. Food and Drug Administration's Metabolic Drugs Advisory Committee, now rescheduled to May 27.

"The FDA has indicated that the action goal date, which is the target date for the FDA to complete its review of the tesamorelin NDA, will be extended to July 27," the company said in a statement.

Theratechnologies shares were trading unchanged at C$4.67 Thursday morning on the Toronto Stock Exchange. (Reporting by Ashutosh Joshi in Bangalore; Editing by Anthony Kurian)